Depot medroxyprogesterone acetate for contraception

INTRODUCTION

Depot medroxyprogesterone acetate (DMPA) is an injectable, progestin-only contraceptive that provides highly effective, private, relatively long-acting (three months), reversible contraception. Use of DMPA eliminates both the need for user action daily or near the time of sexual intercourse and the need for partner cooperation.

DMPA is a good contraceptive option for the following groups of women:

Women who do not want to take a contraceptive pill daily

Women who have a contraindication to, or wish to avoid, an estrogen-containing contraceptive

Women who would like to eliminate regular menses

                                           

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jul 2014. | This topic last updated: Jul 15, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Mishell DR Jr. Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med 1996; 41:381.
  2. Ortiz A, Hirol M, Stanczyk FZ, et al. Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA. J Clin Endocrinol Metab 1977; 44:32.
  3. DEPO-PROVERA- medroxyprogesterone acetate injection http://labeling.pfizer.com/ShowLabeling.aspx?id=522 (Accessed on July 11, 2014).
  4. Shelton JD, Halpern V. Subcutaneous DMPA: a better lower dose approach. Contraception 2014; 89:341.
  5. Prabhakaran S, Sweet A. Self-administration of subcutaneous depot medroxyprogesterone acetate for contraception: feasibility and acceptability. Contraception 2012; 85:453.
  6. Cameron ST, Glasier A, Johnstone A. Pilot study of home self-administration of subcutaneous depo-medroxyprogesterone acetate for contraception. Contraception 2012; 85:458.
  7. Beasley A, White KO, Cremers S, Westhoff C. Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate. Contraception 2014; 89:352.
  8. Keith B, Wood S, Tifft S, Hutchings J. Home-based administration of Sayana® Press: review and assessment of needs in low-resource settings. Contraception 2014; 89:344.
  9. Speroff, L, Darney, PD. Injectable contraception. In: A Clinical Guide for Contraception. Philadelphia, Pa: Lippincott Williams & Wilkins; 2011: chap 6.
  10. Kaunitz AM. Long-acting injectable contraception with depot medroxyprogesterone acetate. Am J Obstet Gynecol 1994; 170:1543.
  11. Trussell J. Contraceptive failure in the United States. Contraception 2004; 70:89.
  12. World Health Organization Department of Reproductive Health and Research and Johns Hopkins Bloomberg School of Public Health. Family Planning: A Global Handbook for Providers (2008 update). Baltimore and Geneva, 2008.
  13. Winner B, Peipert JF, Zhao Q, et al. Effectiveness of long-acting reversible contraception. N Engl J Med 2012; 366:1998.
  14. Leiman G. Depo-medroxyprogesterone acetate as a contraceptive agent: its effect on weight and blood pressure. Am J Obstet Gynecol 1972; 114:97.
  15. Segall-Gutierrez P, Taylor D, Liu X, et al. Follicular development and ovulation in extremely obese women receiving depo-medroxyprogesterone acetate subcutaneously. Contraception 2010; 81:487.
  16. Sapire, KE. Letter to the Editor: Depo-Provera and carbamazepine. Br J Fam Plann 1990; 15:130.
  17. Jain J, Jakimiuk AJ, Bode FR, et al. Contraceptive efficacy and safety of DMPA-SC. Contraception 2004; 70:269.
  18. Kaunitz AM, Darney PD, Ross D, et al. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density. Contraception 2009; 80:7.
  19. US Selected Practice Recommendations for Contraceptive Use, 2013. http://www.cdc.gov/mmwr/pdf/rr/rr62e0614.pdf. (Accessed on June 14, 2013).
  20. Halpern V, Combes SL, Dorflinger LJ, et al. Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm. Contraception 2014; 89:31.
  21. Williams RL, Hensel DJ, Fortenberry JD. Self-administration of subcutaneous depot medroxyprogesterone acetate by adolescent women. Contraception 2013; 88:401.
  22. Borgatta L, Murthy A, Chuang C, et al. Pregnancies diagnosed during Depo-Provera use. Contraception 2002; 66:169.
  23. Brent RL. Nongenital malformations following exposure to progestational drugs: the last chapter of an erroneous allegation. Birth Defects Res A Clin Mol Teratol 2005; 73:906.
  24. Kapp N, Gaffield ME. Initiation of progestogen-only injectables on different days of the menstrual cycle and its effect on contraceptive effectiveness and compliance: a systematic review. Contraception 2013; 87:576.
  25. Sneed R, Westhoff C, Morroni C, Tiezzi L. A prospective study of immediate initiation of depo medroxyprogesterone acetate contraceptive injection. Contraception 2005; 71:99.
  26. Balkus J, Miller L. Same-day administration of depot-medroxyprogesterone acetate injection: a retrospective chart review. Contraception 2005; 71:395.
  27. Nelson AL, Katz T. Initiation and continuation rates seen in 2-year experience with Same Day injections of DMPA. Contraception 2007; 75:84.
  28. Rickert VI, Tiezzi L, Lipshutz J, et al. Depo Now: preventing unintended pregnancies among adolescents and young adults. J Adolesc Health 2007; 40:22.
  29. Lopez LM, Newmann SJ, Grimes DA, et al. Immediate start of hormonal contraceptives for contraception. Cochrane Database Syst Rev 2012; 12:CD006260.
  30. World Health Organization. Selected practice recommendations for contraceptive use. 2nd edition, 2004. http://whqlibdoc.who.int/publications/2004/9241562846.pdf (Accessed on June 03, 2011).
  31. Steiner MJ, Kwok C, Stanback J, et al. Injectable contraception: what should the longest interval be for reinjections? Contraception 2008; 77:410.
  32. Goldberg AB, Grimes DA. Injectable contraceptives. In: Contraceptive Technology, 19th, Hatcher RA, Trussell J, Nelson AL, et al. (Eds), Ardent Media, New York 2007. p.157.
  33. Schwallie PC, Assenzo JR. The effect of depo-medroxyprogesterone acetate on pituitary and ovarian function, and the return of fertility following its discontinuation: a review. Contraception 1974; 10:181.
  34. Lei ZW, Wu SC, Garceau RJ, et al. Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception. Contraception 1996; 53:357.
  35. Hubacher D, Goco N, Gonzalez B, Taylor D. Factors affecting continuation rates of DMPA. Contraception 1999; 60:345.
  36. Canto De Cetina TE, Canto P, Ordoñez Luna M. Effect of counseling to improve compliance in Mexican women receiving depot-medroxyprogesterone acetate. Contraception 2001; 63:143.
  37. Westfall JM, Main DS, Barnard L. Continuation rates among injectable contraceptive users. Fam Plann Perspect 1996; 28:275.
  38. Polaneczky M, Guarnaccia M, Alon J, Wiley J. Early experience with the contraceptive use of depot medroxyprogesterone acetate in an inner-city clinic population. Fam Plann Perspect 1996; 28:174.
  39. Hubacher D, Lopez L, Steiner MJ, Dorflinger L. Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence-based comparisons. Contraception 2009; 80:113.
  40. Kaunitz AM. Menstruation: choosing whether...and when. Contraception 2000; 62:277.
  41. Glasier AF, Smith KB, van der Spuy ZM, et al. Amenorrhea associated with contraception-an international study on acceptability. Contraception 2003; 67:1.
  42. Smith, RD, Cromer, BA, Hayes, MA, et al. Medroxyprogesterone acetate (Depo-Provera) use in adolescents: Uterine bleeding and blood pressure patterns, patient satisfaction, and continuation rates. Adolesc Pediatr Gynecol 1993; 8:24.
  43. Nelson AL. Counseling issues and management of side effects for women using depot medroxyprogesterone acetate contraception. J Reprod Med 1996; 41:391.
  44. Nelson, AS, Zieman, M. DMPA: Has it been a decade already? The Female Patient 2002; 27:57.
  45. Lopez LM, Edelman A, Chen M, et al. Progestin-only contraceptives: effects on weight. Cochrane Database Syst Rev 2013; 7:CD008815.
  46. Vickery Z, Madden T, Zhao Q, et al. Weight change at 12 months in users of three progestin-only contraceptive methods. Contraception 2013; 88:503.
  47. Steenland MW, Zapata LB, Brahmi D, et al. Appropriate follow up to detect potential adverse events after initiation of select contraceptive methods: a systematic review. Contraception 2013; 87:611.
  48. Pelkman CL, Chow M, Heinbach RA, Rolls BJ. Short-term effects of a progestational contraceptive drug on food intake, resting energy expenditure, and body weight in young women. Am J Clin Nutr 2001; 73:19.
  49. Crosignani PG, Luciano A, Ray A, Bergqvist A. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod 2006; 21:248.
  50. Schlaff WD, Carson SA, Luciano A, et al. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril 2006; 85:314.
  51. Kaunitz AM. Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians. Int J Fertil Womens Med 1998; 43:73.
  52. Martin VT, Behbehani M. Ovarian hormones and migraine headache: understanding mechanisms and pathogenesis--part 2. Headache 2006; 46:365.
  53. Civic D, Scholes D, Ichikawa L, et al. Depressive symptoms in users and non-users of depot medroxyprogesterone acetate. Contraception 2000; 61:385.
  54. Westhoff C. Depot medroxyprogesterone acetate contraception. Metabolic parameters and mood changes. J Reprod Med 1996; 41:401.
  55. Westhoff C, Truman C, Kalmuss D, et al. Depressive symptoms and Depo-Provera. Contraception 1998; 57:237.
  56. Gupta N, O'Brien R, Jacobsen LJ, et al. Mood changes in adolescents using depot-medroxyprogesterone acetate for contraception: a prospective study. J Pediatr Adolesc Gynecol 2001; 14:71.
  57. Moore LL, Valuck R, McDougall C, Fink W. A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives. Contraception 1995; 52:215.
  58. Björn I, Bixo M, Nöjd KS, et al. Negative mood changes during hormone replacement therapy: a comparison between two progestogens. Am J Obstet Gynecol 2000; 183:1419.
  59. North American Menopause Society. Role of progestogen in hormone therapy for postmenopausal women: position statement of The North American Menopause Society. Menopause 2003; 10:113.
  60. Clark MK, Sowers M, Levy BT, Tenhundfeld P. Magnitude and variability of sequential estradiol and progesterone concentrations in women using depot medroxyprogesterone acetate for contraception. Fertil Steril 2001; 75:871.
  61. Gbolade BA. Depo-Provera and bone density. J Fam Plann Reprod Health Care 2002; 28:7.
  62. Baeten JM, Nyange PM, Richardson BA, et al. Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study. Am J Obstet Gynecol 2001; 185:380.
  63. Scholes D, LaCroix AZ, Ichikawa LE, et al. Injectable hormone contraception and bone density: results from a prospective study. Epidemiology 2002; 13:581.
  64. Clark MK, Sowers MR, Nichols S, Levy B. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Fertil Steril 2004; 82:1580.
  65. Clark MK, Sowers M, Levy B, Nichols S. Bone mineral density loss and recovery during 48 months in first-time users of depot medroxyprogesterone acetate. Fertil Steril 2006; 86:1466.
  66. Ulrich CM, Georgiou CC, Snow-Harter CM, Gillis DE. Bone mineral density in mother-daughter pairs: relations to lifetime exercise, lifetime milk consumption, and calcium supplements. Am J Clin Nutr 1996; 63:72.
  67. Cromer BA, Bonny AE, Stager M, et al. Bone mineral density in adolescent females using injectable or oral contraceptives: a 24-month prospective study. Fertil Steril 2008; 90:2060.
  68. Kaunitz AM, Miller PD, Rice VM, et al. Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception 2006; 74:90.
  69. Berenson AB, Radecki CM, Grady JJ, et al. A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Obstet Gynecol 2001; 98:576.
  70. Westhoff C. Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraceptive option with proven long-term safety. Contraception 2003; 68:75.
  71. Cundy T, Cornish J, Roberts H, et al. Spinal bone density in women using depot medroxyprogesterone contraception. Obstet Gynecol 1998; 92:569.
  72. Cundy T, Evans M, Roberts H, et al. Bone density in women receiving depot medroxyprogesterone acetate for contraception. BMJ 1991; 303:13.
  73. Petitti DB, Piaggio G, Mehta S, et al. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. The WHO Study of Hormonal Contraception and Bone Health. Obstet Gynecol 2000; 95:736.
  74. Scholes D, LaCroix AZ, Ichikawa LE, et al. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med 2005; 159:139.
  75. Orr-Walker BJ, Evans MC, Ames RW, et al. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. Clin Endocrinol (Oxf) 1998; 49:615.
  76. Rosenberg L, Zhang Y, Constant D, et al. Bone status after cessation of use of injectable progestin contraceptives. Contraception 2007; 76:425.
  77. Berenson AB, Breitkopf CR, Grady JJ, et al. Effects of hormonal contraception on bone mineral density after 24 months of use. Obstet Gynecol 2004; 103:899.
  78. Cromer BA, Stager M, Bonny A, et al. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J Adolesc Health 2004; 35:434.
  79. Sanches L, Marchi NM, Castro S, et al. Forearm bone mineral density in postmenopausal former users of depot medroxyprogesterone acetate. Contraception 2008; 78:365.
  80. Harel Z, Johnson CC, Gold MA, et al. Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections. Contraception 2010; 81:281.
  81. Viola AS, Castro S, Marchi NM, et al. Long-term assessment of forearm bone mineral density in postmenopausal former users of depot medroxyprogesterone acetate. Contraception 2011; 84:122.
  82. Kaunitz AM, Arias R, McClung M. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception 2008; 77:67.
  83. Lappe JM, Stegman MR, Recker RR. The impact of lifestyle factors on stress fractures in female Army recruits. Osteoporos Int 2001; 12:35.
  84. Watson KC, Lentz MJ, Cain KC. Associations between fracture incidence and use of depot medroxyprogesterone acetate and anti-epileptic drugs in women with developmental disabilities. Womens Health Issues 2006; 16:346.
  85. Vestergaard P, Rejnmark L, Mosekilde L. The effects of depot medroxyprogesterone acetate and intrauterine device use on fracture risk in Danish women. Contraception 2008; 78:459.
  86. Meier C, Brauchli YB, Jick SS, et al. Use of depot medroxyprogesterone acetate and fracture risk. J Clin Endocrinol Metab 2010; 95:4909.
  87. Lanza LL, McQuay LJ, Rothman KJ, et al. Use of depot medroxyprogesterone acetate contraception and incidence of bone fracture. Obstet Gynecol 2013; 121:593.
  88. Paschall S, Kaunitz AM. Depo-Provera and skeletal health: a survey of Florida obstetrics and gynecologist physicians. Contraception 2008; 78:370.
  89. ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006; 107:1453.
  90. World Health Organization. WHO Statement on Hormonal Contraception and Bone Health 2005; 1-2.
  91. Black A, Ad Hoc DMPA Committee of the Society of Obstetricians and Gynaecologists of Canada. Canadian contraception consensus--update on Depot Medroxyprogesterone Acetate (dmpa). J Obstet Gynaecol Can 2006; 28:305.
  92. Cromer BA, Scholes D, Berenson A, et al. Depot medroxyprogesterone acetate and bone mineral density in adolescents--the Black Box Warning: a Position Paper of the Society for Adolescent Medicine. J Adolesc Health 2006; 39:296.
  93. Guilbert ER, Brown JP, Kaunitz AM, et al. The use of depot-medroxyprogesterone acetate in contraception and its potential impact on skeletal health. Contraception 2009; 79:167.
  94. Committee Opinion No. 602: Depot medroxyprogesterone acetate and bone effects. Obstet Gynecol 2014; 123:1398.
  95. Karlsson C, Obrant KJ, Karlsson M. Pregnancy and lactation confer reversible bone loss in humans. Osteoporos Int 2001; 12:828.
  96. Sowers M, Corton G, Shapiro B, et al. Changes in bone density with lactation. JAMA 1993; 269:3130.
  97. Cromer BA, Lazebnik R, Rome E, et al. Double-blinded randomized controlled trial of estrogen supplementation in adolescent girls who receive depot medroxyprogesterone acetate for contraception. Am J Obstet Gynecol 2005; 192:42.
  98. Cundy T, Ames R, Horne A, et al. A randomized controlled trial of estrogen replacement therapy in long-term users of depot medroxyprogesterone acetate. J Clin Endocrinol Metab 2003; 88:78.
  99. Aries, RD, Kaunitz, AM, McClung, MR. Depot medroxyprogesterone acetate and bone density. Dialogues in contraception 2007; 11:1.
  100. Cullins VE. Noncontraceptive benefits and therapeutic uses of depot medroxyprogesterone acetate. J Reprod Med 1996; 41:428.
  101. Muse K. Hormonal manipulation in the treatment of premenstrual syndrome. Clin Obstet Gynecol 1992; 35:658.
  102. Johnson SR. Premenstrual syndrome, premenstrual dysphoric disorder, and beyond: a clinical primer for practitioners. Obstet Gynecol 2004; 104:845.
  103. Küçük T, Ertan K. Continuous oral or intramuscular medroxyprogesterone acetate versus the levonorgestrel releasing intrauterine system in the treatment of perimenopausal menorrhagia: a randomized, prospective, controlled clinical trial in female smokers. Clin Exp Obstet Gynecol 2008; 35:57.
  104. Venkatachalam S, Bagratee JS, Moodley J. Medical management of uterine fibroids with medroxyprogesterone acetate (Depo Provera): a pilot study. J Obstet Gynaecol 2004; 24:798.
  105. Vercellini P, De Giorgi O, Oldani S, et al. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. Am J Obstet Gynecol 1996; 175:396.
  106. Sönmezer M, Atabekoğlu C, Cengiz B, et al. Depot-medroxyprogesterone acetate in anticoagulated patients with previous hemorrhagic corpus luteum. Eur J Contracept Reprod Health Care 2005; 10:9.
  107. Culwell KR, Curtis KM. Use of contraceptive methods by women with current venous thrombosis on anticoagulant therapy: a systematic review. Contraception 2009; 80:337.
  108. Elkins TE, Gafford LS, Wilks CS, et al. A model clinic approach to the reproductive health concerns of the mentally handicapped. Obstet Gynecol 1986; 68:185.
  109. De Ceulaer K, Gruber C, Hayes R, Serjeant GR. Medroxyprogesterone acetate and homozygous sickle-cell disease. Lancet 1982; 2:229.
  110. Manchikanti A, Grimes DA, Lopez LM, Schulz KF. Steroid hormones for contraception in women with sickle cell disease. Cochrane Database Syst Rev 2007; :CD006261.
  111. Mattson RH, Cramer JA, Caldwell BV, Siconolfi BC. Treatment of seizures with medroxyprogesterone acetate: preliminary report. Neurology 1984; 34:1255.
  112. Frederiksen MC. Depot medroxyprogesterone acetate contraception in women with medical problems. J Reprod Med 1996; 41:414.
  113. North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause 2004; 11:11.
  114. Lestishock L, Pariseau C, Rooholamini S, Ammerman S. Anaphylaxis from depot medroxyprogesterone acetate in an adolescent girl. Obstet Gynecol 2011; 118:443.
  115. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer 1991; 49:186.
  116. Depot-medroxyprogesterone acetate (DMPA) and risk of epithelial ovarian cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer 1991; 49:191.
  117. Depot-medroxyprogesterone acetate (DMPA) and risk of invasive squamous cell cervical cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Contraception 1992; 45:299.
  118. Breast cancer and depot-medroxyprogesterone acetate: a multinational study. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Lancet 1991; 338:833.
  119. Shapiro S, Rosenberg L, Hoffman M, et al. Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives. Am J Epidemiol 2000; 151:396.
  120. Strom BL, Berlin JA, Weber AL, et al. Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer. Contraception 2004; 69:353.
  121. Paul C, Skegg DC, Spears GF. Depot medroxyprogesterone (Depo-Provera) and risk of breast cancer. BMJ 1989; 299:759.
  122. Lee NC, Rosero-Bixby L, Oberle MW, et al. A case-control study of breast cancer and hormonal contraception in Costa Rica. J Natl Cancer Inst 1987; 79:1247.
  123. Li CI, Beaber EF, Tang MT, et al. Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age. Cancer Res 2012; 72:2028.
  124. Eaton SB, Pike MC, Short RV, et al. Women's reproductive cancers in evolutionary context. Q Rev Biol 1994; 69:353.
  125. Liang AP, Levenson AG, Layde PM, et al. Risk of breast, uterine corpus, and ovarian cancer in women receiving medroxyprogesterone injections. JAMA 1983; 249:2909.
  126. Wilailak S, Vipupinyo C, Suraseranivong V, et al. Depot medroxyprogesterone acetate and epithelial ovarian cancer: a multicentre case-control study. BJOG 2012; 119:672.
  127. Kongsayreepong R, Chutivongse S, George P, et al. A multicentre comparative study of serum lipids and apolipoproteins in long-term users of DMPA and a control group of IUD users. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation Special Programme of Research, Development and Research Training in Human Reproduction. Contraception 1993; 47:177.
  128. Enk L, Landgren BM, Lindberg UB, et al. A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids. Horm Metab Res 1992; 24:85.
  129. Berenson AB, Rahman M, Wilkinson G. Effect of injectable and oral contraceptives on serum lipids. Obstet Gynecol 2009; 114:786.
  130. Lizarelli PM, Martins WP, Vieira CS, et al. Both a combined oral contraceptive and depot medroxyprogesterone acetate impair endothelial function in young women. Contraception 2009; 79:35.
  131. Yadav BK, Gupta RK, Gyawali P, et al. Effects of long-term use of depo-medroxyprogesterone acetate on lipid metabolism in Nepalese women. Korean J Lab Med 2011; 31:95.
  132. Goldstein J, Cushman M, Badger GJ, Johnson JV. Effect of depomedroxyprogesterone acetate on coagulation parameter: a pilot study. Fertil Steril 2007; 87:1267.
  133. Taneepanichskul S, Reinprayoon D, Jaisamrarn U. Effects of DMPA on weight and blood pressure in long-term acceptors. Contraception 1999; 59:301.
  134. Whigham KA, Howie PW, Mack A, Prentice CR. The effect of an injectable progestogen contraceptive on blood coagulation and fibrinolysis. Br J Obstet Gynaecol 1979; 86:806.
  135. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception 1998; 57:315.
  136. van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol 2010; 30:2297.
  137. Grimes DA, Schulz KF. Surrogate end points in clinical research: hazardous to your health. Obstet Gynecol 2005; 105:1114.
  138. Myer L, Denny L, Wright TC, Kuhn L. Prospective study of hormonal contraception and women's risk of HIV infection in South Africa. Int J Epidemiol 2007; 36:166.
  139. Kleinschmidt I, Rees H, Delany S, et al. Injectable progestin contraceptive use and risk of HIV infection in a South African family planning cohort. Contraception 2007; 75:461.
  140. Morrison CS, Richardson BA, Mmiro F, et al. Hormonal contraception and the risk of HIV acquisition. AIDS 2007; 21:85.
  141. Mostad SB, Overbaugh J, DeVange DM, et al. Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet 1997; 350:922.
  142. Wang CC, McClelland RS, Overbaugh J, et al. The effect of hormonal contraception on genital tract shedding of HIV-1. AIDS 2004; 18:205.
  143. Heffron R, Donnell D, Rees H, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis 2011.
  144. WHO Technical Statement. Hormonal contraception and HIV. February 2012. http://www.who.int/reproductivehealth/topics/family_planning/hc_hiv/en/index.html (Accessed on March 06, 2012).
  145. Centers for Disease Control and Prevention (CDC). Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: revised recommendations for the use of hormonal contraception among women at high risk for HIV infection or infected with HIV. MMWR Morb Mortal Wkly Rep 2012; 61:449.
  146. Clark RA, Kissinger P, Williams T. Contraceptive and sexually transmitted diseases protection among adult and adolescent women infected with human immunodeficiency virus. Int J STD AIDS 1996; 7:439.
  147. Lavreys L, Chohan V, Overbaugh J, et al. Hormonal contraception and risk of cervical infections among HIV-1-seropositive Kenyan women. AIDS 2004; 18:2179.
  148. Overton ET, Shacham E, Singhatiraj E, Nurutdinova D. Incidence of sexually transmitted infections among HIV-infected women using depot medroxyprogesterone acetate contraception. Contraception 2008; 78:125.
  149. Morrison CS, Bright P, Wong EL, et al. Hormonal contraceptive use, cervical ectopy, and the acquisition of cervical infections. Sex Transm Dis 2004; 31:561.
  150. Mauck CK, Callahan MM, Baker J, et al. The effect of one injection of Depo-Provera on the human vaginal epithelium and cervical ectopy. Contraception 1999; 60:15.
  151. Berenson AB, van den Berg P, Williams KJ, Rahman M. Effect of injectable and oral contraceptives on glucose and insulin levels. Obstet Gynecol 2011; 117:41.
  152. Xiang AH, Kawakubo M, Kjos SL, Buchanan TA. Long-acting injectable progestin contraception and risk of type 2 diabetes in Latino women with prior gestational diabetes mellitus. Diabetes Care 2006; 29:613.
  153. Cromer BA, Smith RD, Blair JM, et al. A prospective study of adolescents who choose among levonorgestrel implant (Norplant), medroxyprogesterone acetate (Depo-Provera), or the combined oral contraceptive pill as contraception. Pediatrics 1994; 94:687.
  154. Davis AJ. Use of depot medroxyprogesterone acetate contraception in adolescents. J Reprod Med 1996; 41:407.
  155. O'Dell, C, Forke, C, Polaneczky, M, et al. Depo-Provera vs. oral contraceptive use by postpartum adolescents (abstr). J Adolesc Health 1997; 20:127.
  156. Chotnopparatpattara P, Taneepanichskul S. Use of depot medroxyprogesterone acetate in Thai adolescents. Contraception 2000; 62:137.
  157. Kaunitz AM. Long-acting hormonal contraceptives--indispensable in preventing teen pregnancy. J Adolesc Health 2007; 40:1.
  158. Tolaymat LL, Kaunitz AM. Long-acting contraceptives in adolescents. Curr Opin Obstet Gynecol 2007; 19:453.
  159. Templeman CL, Cook V, Goldsmith LJ, et al. Postpartum contraceptive use among adolescent mothers. Obstet Gynecol 2000; 95:770.
  160. Stevens-Simon C, Kelly L, Kulick R. A village would be nice but...it takes a long-acting contraceptive to prevent repeat adolescent pregnancies. Am J Prev Med 2001; 21:60.
  161. McKinlay SM, Bifano NL, McKinlay JB. Smoking and age at menopause in women. Ann Intern Med 1985; 103:350.
  162. Stanford JL, Hartge P, Brinton LA, et al. Factors influencing the age at natural menopause. J Chronic Dis 1987; 40:995.
  163. Bastian LA, Smith CM, Nanda K. Is this woman perimenopausal? JAMA 2003; 289:895.
  164. Juliato CT, Fernandes A, Marchi NM, et al. Usefulness of FSH measurements for determining menopause in long-term users of depot medroxyprogesterone acetate over 40 years of age. Contraception 2007; 76:282.
  165. Pérez-Palacios G, Fernández-Aparicio MA, Medina M, et al. On the mechanism of action of progestins. Acta Endocrinol (Copenh) 1981; 97:320.
  166. Chiou CF, Trussell J, Reyes E, et al. Economic analysis of contraceptives for women. Contraception 2003; 68:3.